Intuitive Surgical, Inc.

🇺🇸NASDAQ Global Select
Back to all articles
Intuitive Surgical, Inc. stock analysis ISRG overview
Slightly Bullish +25

Assessing Intuitive Surgical (ISRG) Valuation As Recent Share Price Weakness Meets Strong Long Term Returns

📉 Intuitive Surgical (ISRG) has faced recent share price weakness with a 18.54% decline year-to-date and a 2.8% drop over the last week.

💹 The stock currently trades at $457.78, though Tokyo's analysis pegs its fair value at $532.46, suggesting it is modestly undervalued.

🤖 A global installed base of 9,539 da Vinci systems continues to grow annually at a rate of 15.1%.

📈 These systems are performing approximately 2.2 million procedures per year, with procedure volume growth accelerating at 22.2% annually.

💰 Intuitive Surgical trades at a P/E multiple of 54.4x, which is double that of the broader US medical equipment sector average of 23.6x.

⚖️ The high valuation premium implies significant sensitivity to any changes in earnings expectations or growth assumptions.

📉 Investors are reassessing whether current prices reflect a fresh entry point or if future growth has already been fully priced in by the market.

🏥 Risks to the long-term narrative include potential slowdowns in procedure volumes or delays in hospital spending on new and existing systems.

💼 The company's recurring revenue model from installed da Vinci systems is considered a key differentiator driving its valuation.

📊 Simply Wall St recommends diversifying into other robotics, automation, and high-quality stocks to mitigate concentration risk.

⚠️ The article includes a disclaimer that the analysis uses historical data and analyst forecasts but does not constitute financial advice.

Bullish Signals
  • Intuitive Surgical boasts strong long-term performance with a 3-year total shareholder return of 51.04% and a 5-year total shareholder return of 64.51%, indicating sustained compounding value despite recent short-term volatility.
  • The installed base of da Vinci systems is growing robustly at an annual rate of 15.1%, with procedure volumes increasing by 22.2% year-over-year to approximately 2.2 million procedures performed annually.
  • Valuation models, such as the Tokyo narrative, peg a fair value of $532.46, suggesting the current share price of roughly $457.78 represents a modest discount and potential upside opportunity.
  • Intuitive Surgical continues to post steady revenue and net income growth while trading at an intrinsic premium that could magnify future gains if high expectations are met.
Risk Factors
  • The stock has experienced significant short-term downside, including an 18.54% decline year-to-date and a 2.8% drop over the last 7 days.
  • Intuitive Surgical trades at a rich P/E ratio of 54.4x, which is substantially higher than the US Medical Equipment industry average of 23.6x and peers' average of 26.1x, creating vulnerability if earnings growth fails to justify the premium.
  • The valuation depends heavily on procedure volumes growing at 22.2% per year; any slowdown in this growth rate could significantly impact the stock price given the high multiple.
  • There is a risk that hospitals may delay capital and service spending on existing or new da Vinci systems, which would directly challenge the recurring revenue narrative supporting the fair value of $532.46.
  • The analysis relies on analyst forecasts and historical data which may not factor in the latest price-sensitive company announcements or recent qualitative material developments.
Full Analysis
Intuitive Surgical (ISRG) is experiencing a period of valuation reassessment following a choppy recent stock price performance, with the share currently trading around $457.78. This marks a year-to-date decline of 18.54%, contrasting sharply with strong longer-term returns including a 51.04% three-year total shareholder return and a 64.51% five-year gain. The core investment thesis highlights the company's growing installed base of da Vinci surgical systems, which now totals 9,539 units globally, growing at an annual rate of 15.1%, and performs approximately 2.2 million procedures annually with procedure volume growing 22.2% per year. A valuation model suggests a fair value price target of $532.46, implying the stock is currently trading at a 14% discount or modestly undervalued despite carrying an expensive multiple. The company trades at a Price-to-Earnings ratio of 54.4x, which is significantly higher than the 23.6x for the broader US Medical Equipment industry and 26.1x for direct peers, indicating investors are paying a substantial premium for its earnings growth prospects. While the strong recurring revenue from established installed bases supports long-term value, the high valuation multiple creates sensitivity to potential slowdowns in procedure volumes or delays in hospital capital spending. The analysis concludes that sentiment is split between short-term weakness and long-term integrity, with key rewards tied to the expanding surgical robotics business needing careful monitoring against market expectations.